Date: 2014-09-04
Type of information: Company acquisition
Acquired company: Cellectis AB (Sweden)
Acquiring company: Takara Bio (Japan)
Amount: undisclosed
Terms: * On September 4, 2014, Cellectis a French company dedicated to the development of adoptive immunotherapies based on engineered allogeneic CART cells (UCART), announced that it has closed the sale of its subsidiary Cellectis AB to Takara Bio Inc. The financials terms have not been disclosed. * On July 29, 2014, Cellectis announced the sale of its subsidiary Cellectis AB (previously Cellartis) to Takara Bio Inc. Cellectis has acquired this Swedish company specialized in stem cell-derived in vitro R&D tools three years ago. The quick downturn of the market had led the French biotech to restructure in 2013 its heavily loss-making “Tools and Services” Business Unit. The sale of Cellectis AB is the last step of the reorganization of this Business Unit which in 2013 recorded an operating loss of 14 million euros before booking of extraordinary depreciation and of the costs related to the company downsizing. The transaction will lead to a loss of about € 5 million in 2014 Cellectis’ books. This operation will be realized in the coming weeks subject to the completion of certain usual conditions.
Details: Cellectis will now go on the extension to its strategic therapeutic focus. The company now concentrates its activities in the field of oncology through the development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy products generated through its allogeneic CAR-T platform, both on its own as well as in partnership with Servier and Pfizer.
Related: stem cells services
